Ten IPOs raised a combined $1.8 billion in August, joined by two direct listings. Activity slowed from July’s pace as the market entered its typical summer slowdown but was slightly above the month’s 10-year historical average (10 IPOs, $1.7B). Six...read more
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
BlossomHill Therapeutics, which is developing small molecule cancer therapies, raised $150 million in an upsized IPO by offering 9.4 million shares at $16, the midpoint of the $15 to $17 range. The San Diego, CA-based company originally filed to offer 7.8...read more
BlossomHill Therapeutics, a Phase 2-ready biotech developing small molecule cancer therapies, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17. At...read more
Renaissance Capital’s August IPO Market Update
Ten IPOs raised a combined $1.8 billion in August, joined by two direct listings. Activity slowed from July’s pace as the market entered its typical summer slowdown but was slightly above the month’s 10-year historical average (10 IPOs, $1.7B). Six...read more
US IPO Weekly Recap: August kicks off with flurry of biotech IPOs
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
BlossomHill Therapeutics prices upsized IPO at $16, the midpoint of the range
BlossomHill Therapeutics, which is developing small molecule cancer therapies, raised $150 million in an upsized IPO by offering 9.4 million shares at $16, the midpoint of the $15 to $17 range. The San Diego, CA-based company originally filed to offer 7.8...read more
Cancer biotech BlossomHill Therapeutics sets terms for $125 million IPO
BlossomHill Therapeutics, a Phase 2-ready biotech developing small molecule cancer therapies, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17. At...read more